Catalyst Pharmaceuticals, Inc. provided earnings guidance for the year 2022. For the year, total revenues will be in the range of between $195 million and $205 million, representing a 38% - 45% increase in total revenues compared to 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.9 USD | -0.09% | -3.52% | -5.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.35% | 1.88B | |
-2.00% | 90.27B | |
-1.18% | 40.12B | |
-15.84% | 31.75B | |
+62.86% | 26.6B | |
-21.69% | 14.41B | |
-8.42% | 12.92B | |
-15.05% | 11.44B | |
-45.69% | 11.3B | |
+4.94% | 8.87B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022